Neuraxis (NRXS) Stock News, May-Sep 2025

NeurAxis (NYSE American: NRXS) reported strong Q2 2025 financial results, with revenues increasing 46% year-over-year to $894,000. The medical technology company, focused on neuromodulation therapies, achieved significant milestones including FDA clearance for expanded pediatric treatment and secured key academic society guidelines recommendation for their PENFS technology.

Operating expenses decreased 10% year-over-year, while operating loss improved by 22%. The company maintained a cash balance of $6 million, bolstered by a $5 million equity financing round. NeurAxis expanded its covered lives to 53 million and received a new Category I CPT code for PENFS procedures, effective January 2026. The company expects to achieve breakeven in 2026.

NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions, has scheduled its Q2 2025 earnings call for Tuesday, August 12, 2025, at 9:00 AM ET. The financial results will be released before the market opens.

The company will host a live webcast accessible through their investor relations website, with options for participants to submit questions through the webcast portal or via email. A replay of the webcast will be available on the company's website following the call.

NeurAxis (NYSE: NRXS) has secured medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology from two health insurers, adding 700,000 covered lives in Connecticut and Massachusetts. This brings their total national coverage to approximately 53 million members. The company's FDA-cleared IB-Stim device treats functional abdominal pain associated with IBS and Pediatric Functional Dyspepsia in patients aged 8-21 years through non-surgical electrical stimulation of cranial nerves. The technology has been included in pediatric academic society's treatment guidelines, and a Category I CPT code will become effective January 1, 2026, which is expected to improve reimbursement and adoption across children's hospitals.

NeurAxis (NRXS) has achieved a significant milestone as its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been included in new clinical practice guidelines for treating Functional Abdominal Pain in IBS. The guidelines, published in the Journal of Pediatric Gastroenterology & Nutrition, recommend PENFS as one of only four highest-evidence therapies. NeurAxis's IB-Stim is the only FDA-cleared treatment recommended in the guidelines for pediatrics, targeting patients aged 8-21. This recognition is expected to facilitate widespread insurance coverage and market adoption. The company estimates a $3 billion addressable market in the US alone, with over 600,000 affected children. The guidelines were developed collaboratively by European and North American pediatric gastroenterology societies using the WHO-supported GRADE approach.

NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.

The company will deliver a webcast presentation at 9:30 a.m. ET and conduct one-on-one meetings with investors throughout the event. Interested parties can access the webcast through the conference website or directly via the provided link, with replay options available after the event.

NeurAxis (NYSE: NRXS) has successfully closed a registered direct offering of 1,538,461 shares of common stock at $3.25 per share, raising approximately $5.0 million in gross proceeds. The company also secured over $1 million from warrant exercises in the same week. This financing follows the recent FDA clearance expanding indications for IB-Stim treatment of Pediatric Functional Abdominal Pain (FAP). The company plans to implement a CPT Category I code effective January 1, 2026. Craig-Hallum Capital Group served as the exclusive placement agent for the offering, which was conducted under a shelf registration statement previously filed with the SEC.

NeurAxis (NYSE: NRXS), a medical technology company focused on neuromodulation therapies, has announced a $5.0 million registered direct offering of 1,538,461 common stock shares priced at $3.25 per share. The offering, expected to close around May 22, 2025, is being conducted through Craig-Hallum Capital Group as the exclusive placement agent.

The company plans to use the net proceeds for working capital and general corporate purposes. The offering is made under a shelf registration statement filed with the SEC in December 2024 and declared effective in February 2025.

NeurAxis (NYSE: NRXS) has achieved a significant milestone with FDA 510(k) clearance for IB-Stim™ to treat Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia and related nausea symptoms in patients aged 8-21 years. This marks the first-ever FDA clearance for functional dyspepsia treatment and represents the company's second expanded FDA indication. The new approval is expected to nearly double the company's total addressable market. IB-Stim, utilizing PENFS technology, is a non-surgical device that delivers gentle electrical impulses to cranial nerve bundles in the ear. The commercial rollout will leverage existing CPT codes, insurance coverage, and provider infrastructure, enabling a capital-efficient market strategy. Notably, a new CPT Category I code for IB-Stim will take effect in January 2026, further strengthening its market position.

NeurAxis (NYSE: NRXS) reported strong Q1 2025 financial results with revenues increasing 39% year-over-year to $896,000. The company achieved significant operational milestones, including expanding covered lives to 51 million from 4 million in December 2023. Key developments include receiving a new CPT Category I code for PENFS procedures (effective January 2026), FDA clearance for expanded IB-Stim label (ages 8-21), and 510(k) clearance for their rectal expulsion device (RED). The company's operating loss improved by 9% YoY (excluding one-time legal settlement), though gross margin declined to 84.4% from 88.4%. With $2.0 million cash on hand and no long-term debt, NeurAxis is treating 300 patients quarterly through PO/PAP programs, representing just 0.2% of their 600,000 potential patient market.